Angiotensin I-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR

Hypertension

Volumn 35, Issue 1 II, 2000, Pages 202-208

  Wang, Hongwei ^a   Reaves, Phyllis Y ^a   Gardon, Monica L ^a   Keene, Kimberley ^a   Goldberg, Drew S ^a   Gelband, Craig H ^a   Katovich, Michael J ^b   Raizada, Mohan K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cardiac hypertrophy; Hypertension; Renovascular responsiveness; SHR; Viral delivery

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; ENDOTHELIUM LESION; EXCITATION CONTRACTION COUPLING; FEMALE; GENE TARGETING; GENE THERAPY; GENOME; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NEWBORN; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGENY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; VERTICAL TRANSMISSION;

EID: 0033966179     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.35.1.202     Document Type: Conference Paper

References (27)

1. Barbagallo M, Novo S, Licata G, Resnick LM. Diabetes, hypertension and atherosclerosis: pathophysiological role of intracellular ions. Int Angiol. 1993;12:365-370.
2. Burnett, JC Jr. Coronary endothelial dysfunction in the hypertensive patient: from myocardial ischemia to heart failure. J Hum Hypertens. 1997;11:45-49.
3. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol. 1999;33(suppl 1):S21-28, S41-43.
4. Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. Regul Pept. 1998;78:1-11.
5. Rothermund L, Paul M. Hypertension and the renin-angiotensin system: evidence from genetic and transgenic studies. Basic Res Cardiol. 1998; 93(suppl 2):1-6.
6. Danser AH. Local renin-angiotensin systems. Mol Cell Biochem. 1996; 157:211-216.
7. Ambrosioni E, Bacchelli S. Clinical pharmacology of angiotensin II antagonists. Cardiologia. 1994;39:401-404.
8. Cosenzi A, Bocin E, Sacerdote A, Plazzotta N, Seculin P, Bernobich E, Solimano N, Ravalico G, Bellini G. Antihypertensive drugs and the nervous system: ACE-inhibitors restore oscillatory potentials in hypertensives. Clin Exp Hypertens. 1999;21:223-231.
9. 1-receptor blockers. J Hum Hypertens. 1999;12(suppl 1):S11-20, S33-34.
10. Roman O. New multicentric studies in hypertension. Rev Med Chil. 1998;126:1238-1246.
11. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983;308:373-376.
12. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
13. Iyer SN, Lu D, Katovich MJ, Raizada MK. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc Natl Acad Sci U S A. 1996;93:9960-9965.
14. Lu D, Raizada MK, Iyer S, Reaves P, Yang H, Katovich MJ. Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension. 1997;30:363-370.
15. Martens JR, Reaves PY, Lu D, Katovich MJ, Berecek KH, Bishop SP, Raizada MK, Gelband CH. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci USA. 1998;95: 2664-2669.
16. Gelband CH, Reaves PY, Evans J, Wang H, Katovich MJ, Raizada, MK. Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension. Hypertension. 1999; 33:360-365.
17. Wang H, Katovich MJ, Gelband CH, Reaves PY, Phillips MI, Raizada MK. Sustained inhibition of angiotensin 1 converting enzyme (ACE) expression by virally mediated delivery of ACE cDNA in rat pulmonary artery endothelial cells. Circ Res. 1999;85:614-622.
18. Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure and vascular protection. Am J Med. 1998;105:27S-31S.
19. Mancini GB. Roles of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med. 1998;105:40S-47S.
20. Mulvany MJ. Effects of angiotensin-converting enzyme inhibition on vascular remodeling of resistance vessels in hypertensive patients. Metabolism. 1998;47(suppl 1):20-23.
21. Pitt B. ACE inhibitors in heart failure: prospects and limitations. Cardiovasc Drugs Ther. 1997;11(suppl 1):285-290.
22. Lin S, Giano N, Culp P, Burns JC, Friedmann T, Yee JK, Hopkins N. Integration and germ-line transmission of a pseudotyped retroviral vector in zebrafish. Science. 1994;265:666-669.
23. Giano N, Allende M, Amsterdam A, Kawakami K, Hopkins N. High efficiency germ-line transmission of proviral insertions in zebrafish. Proc Natl Acad Sci U S A. 1996;93:7777-7782.
24. Lu JK, Burns JC, Chen TT. Pantropic retroviral vector integration, expression, and germ-line transmission in medaka (Dryzias latipes). Mol Mar Biol Biotechnol. 1997;6:289-295.
25. Hrisch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69:475-482.
26. Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues: quantitative analysis by polymerase chain reaction. J Clin Invest 1993;91:2058-2064.
27. Campbell DJ, Anastasopoulous F, Duncan AM, James GM, Kadis A, Briscoe TA. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther. 1998;287:567-577.